BridgeBio (BBIO) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 22, 2026, with virtual participation available to shareholders.

• Shareholders are invited to vote on director elections, executive compensation, auditor ratification, and an amendment to the stock option plan.

Voting matters and shareholder proposals

• Election of three Class I directors to serve until the annual meeting following the year ending December 31, 2028.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval sought for an amendment to increase shares reserved under the 2021 Stock Option and Incentive Plan by 2,000,000 shares.

• Provision to transact other business as may properly come before the meeting.

Board of directors and corporate governance

• Nominees for director are James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D.